WO2004094465A8 - Synthetic molecules that mimic chemokines - Google Patents
Synthetic molecules that mimic chemokinesInfo
- Publication number
- WO2004094465A8 WO2004094465A8 PCT/US2004/012708 US2004012708W WO2004094465A8 WO 2004094465 A8 WO2004094465 A8 WO 2004094465A8 US 2004012708 W US2004012708 W US 2004012708W WO 2004094465 A8 WO2004094465 A8 WO 2004094465A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mimic
- chemokines
- synthetic molecules
- polypeptides
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46471403P | 2003-04-23 | 2003-04-23 | |
US60/464,714 | 2003-04-23 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2004094465A2 WO2004094465A2 (en) | 2004-11-04 |
WO2004094465A8 true WO2004094465A8 (en) | 2004-12-23 |
WO2004094465A3 WO2004094465A3 (en) | 2006-03-02 |
Family
ID=33310942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/012708 WO2004094465A2 (en) | 2003-04-23 | 2004-04-23 | Synthetic molecules that mimic chemokines |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2004094465A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1869066T3 (en) * | 2005-04-08 | 2010-03-29 | Lonza Ag | Peptide synthesis of alpha coils on PEG resin |
EP1991562A2 (en) | 2006-02-27 | 2008-11-19 | Technische Universität München | Cancer imaging and treatment |
US7696309B2 (en) | 2006-10-23 | 2010-04-13 | The Brigham And Women's Hospital, Inc. | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
EP2053060A1 (en) * | 2007-10-24 | 2009-04-29 | Protaffin Biotechnologie AG | SDF-1-based glyocosaminoglycan antagonists and methods of using same |
US8921415B2 (en) | 2009-01-29 | 2014-12-30 | Mapi Pharma Ltd. | Polymorphs of darunavir |
ES2516916T3 (en) * | 2010-01-28 | 2014-10-31 | Mapi Pharma Limited | Procedure for the preparation of darunavir and darunavir intermediates |
WO2011106234A1 (en) | 2010-02-25 | 2011-09-01 | Provasculon, Inc. | Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
WO2012170495A1 (en) | 2011-06-07 | 2012-12-13 | Provasculon, Inc. | Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1 |
LT3007717T (en) * | 2013-06-12 | 2018-11-26 | Pharis Biotec Gmbh | Peptides with antagonistic activities against natural cxcr4 |
CN107325187B (en) * | 2017-07-19 | 2021-11-09 | 黄子为 | Polypeptide with CXCR4 protein agonistic activity and application and pharmaceutical composition thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2751658B1 (en) * | 1996-07-26 | 1998-10-02 | Pasteur Institut | USE OF A LIGAND CHEMOKINE (SDF-1) FOR LESTR / FUSIN / CXCR4 RECEPTOR TO PREVENT OR TREAT INFECTION WITH HIV-LIKE VIRUSES |
MXPA00003885A (en) * | 1997-10-22 | 2004-04-23 | Inst Genetics Llc | Chimeric polypeptides containing chemokine domains. |
JP2002506830A (en) * | 1998-03-13 | 2002-03-05 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | Therapeutic chemokine receptor antagonist |
-
2004
- 2004-04-23 WO PCT/US2004/012708 patent/WO2004094465A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2004094465A2 (en) | 2004-11-04 |
WO2004094465A3 (en) | 2006-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1092467A1 (en) | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n- | |
WO2006124748A3 (en) | Multicyclic compounds and methods of their use | |
WO2004112687A3 (en) | Antiviral acylguanidine compounds and methods | |
WO2004041203A3 (en) | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | |
WO2006073968A3 (en) | Derivatized 3,4-alkylenedioxythiophene monomers, methods of making them, and use thereof | |
WO2004103960A3 (en) | Compounds and uses thereof | |
WO2005097825A3 (en) | Bmp-7 variants with improved properties | |
WO2007076423A3 (en) | INHIBITORS OF Akt ACTIVITY | |
WO2005011592A3 (en) | Substituted indazole-o-glucosides | |
NO20034056D0 (en) | Proliferative diseases | |
MXPA04002982A (en) | Pyrrolidinone derivatives. | |
WO2005012243A3 (en) | Substituted indole-o-glucosides | |
WO2006089665A3 (en) | Active ingredient combinations having insecticide and acaricide properties | |
WO2005063734A3 (en) | Substituted thiophenes | |
NO20050091L (en) | Methods for preparing fibrinogen | |
WO2005074598A3 (en) | Nitroxyl progenitor compounds and methods of use | |
WO2004069152A3 (en) | Δ4,5 glycuronidase and uses thereof | |
NO20035025L (en) | Use of osteopontin for the treatment and / or prevention of neurological diseases, as well as a pharmaceutical composition comprising osteopontin or an antagonist with osteopontin activity. | |
WO2004094465A3 (en) | Synthetic molecules that mimic chemokines | |
EE05357B1 (en) | A tablet containing at least two distinct segments and its use | |
WO2004031352A3 (en) | Interferon variants with improved properties | |
BR0008292A (en) | Mevinoline derivatives | |
WO2004081229A3 (en) | Use of bv8 and/or eg-vegf to promote hematopoiesis | |
WO2004099388A3 (en) | Cbl-b polypeptides, complexes and related methods | |
WO2004065406A3 (en) | Rantes-derived peptides with anti-hiv activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 45/2004 UNDER "PUBLISHED" DELETE "SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELY IN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU" |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |